REGN
$732.87-4.58 (-0.62%)
Regeneron Pharmaceuticals, Inc.
Recent News
This $91 Million Position Signals Conviction in a Biotech Stock Eyeing FDA Decision This Year
This clinical-stage biotech develops therapies for serious immunological diseases, with a focus on late-stage biologic candidates.
Can Alnylam's Pipeline Drugs Sustain Long-Term Growth Ahead?
ALNY's strong drug sales and advancing pipeline, including late-stage candidates, are driving momentum and supporting its long-term growth outlook.
Is Pfizer Inc. (PFE) One of Goldman Sachs Top Healthcare Stocks?
Pfizer Inc. (NYSE:PFE) is one of Goldman Sachs top healthcare stocks. On March 9, analysts at BMO reiterated an Outperform rating on Pfizer Inc. (NYSE:PFE) and a $30 price target. The bullish stance follows positive phase 2 data on the company’s tri-specific antibody tilrekimig. Trial results showed that the once-a-month inhibitor achieved a placebo-adjusted high […]
Is Regeneron Pharmaceuticals, Inc. (REGN) A Good Stock To Buy?
Is REGN a good stock to buy? We came across a bullish thesis on Regeneron Pharmaceuticals, Inc. on Ocular Capital’s Substack. In this article, we will summarize the bulls’ thesis on REGN. Regeneron Pharmaceuticals, Inc.’s share was trading at $774.66 as of March 11th. REGN’s trailing and forward P/E were 18.68 and 18.05, respectively according to Yahoo Finance. […]
Assessing Illumina (ILMN) Valuation After Expanded Genomics And Proteomics Alliance With Regeneron
Illumina (ILMN) is back in focus after expanding its Alliance for Genomic Discovery with Regeneron Genetics Center and launching a dataset of more than 50,000 genomes plus proteomic data using Illumina Protein Prep, targeting multiomic drug discovery research. See our latest analysis for Illumina. Despite the latest alliance news, Illumina’s share price at US$118.94 reflects mixed momentum, with a 2.92% 1 day share price return but a 90 day share price return decline of 11.84%. The 1 year...